Next Article in Journal
Cancer Stem Cells of Differentiated B-Cell Malignancies: Models and Consequences
Next Article in Special Issue
Delineating an Epigenetic Continuum for Initiation, Transformation and Progression to Breast Cancer
Previous Article in Journal
Small Molecule Inhibitors of Bcl-2 Family Proteins for Pancreatic Cancer Therapy
Previous Article in Special Issue
Epigenetic Regulation by Lysine Demethylase 5 (KDM5) Enzymes in Cancer
Article Menu

Export Article

Open AccessArticle
Cancers 2011, 3(2), 1550-1565;

Epigenetic Regulation of Glucose Transporters in Non-Small Cell Lung Cancer

Department of Clinical Medicine, Thoracic Oncology Research Group, Institute of Molecular Medicine, Trinity Centre for Health Sciences, St James´s Hospital, Dublin 8, Ireland
Author to whom correspondence should be addressed.
Received: 25 January 2011 / Revised: 9 February 2011 / Accepted: 9 February 2011 / Published: 25 March 2011
(This article belongs to the Special Issue Epigenetics of Cancer Progression)
Full-Text   |   PDF [368 KB, uploaded 25 March 2011]   |  


Due to their inherently hypoxic environment, cancer cells often resort to glycolysis, or the anaerobic breakdown of glucose to form ATP to provide for their energy needs, known as the Warburg effect. At the same time, overexpression of the insulin receptor in non-small cell lung cancer (NSCLC) is associated with an increased risk of metastasis and decreased survival. The uptake of glucose into cells is carried out via glucose transporters or GLUTs. Of these, GLUT-4 is essential for insulin-stimulated glucose uptake. Following treatment with the epigenetic targeting agents histone deacetylase inhibitors (HDACi), GLUT-3 and GLUT-4 expression were found to be induced in NSCLC cell lines, with minimal responses in transformed normal human bronchial epithelial cells (HBECs). Similar results for GLUT-4 were observed in cells derived from liver, muscle, kidney and pre-adipocytes. Bioinformatic analysis of the promoter for GLUT-4 indicates that it may also be regulated by several chromatin binding factors or complexes including CTCF, SP1 and SMYD3. Chromatin immunoprecipitation studies demonstrate that the promoter for GLUT-4 is dynamically remodeled in response to HDACi. Overall, these results may have value within the clinical setting as (a) it may be possible to use this to enhance fluorodeoxyglucose (18F) positron emission tomography (FDG-PET) imaging sensitivity; (b) it may be possible to target NSCLC through the use of HDACi and insulin mediated uptake of the metabolic targeting drugs such as 2-deoxyglucose (2-DG); or (c) enhance or sensitize NSCLC to chemotherapy. View Full-Text
Keywords: NSCLC; Glucose transporter; epigenetics NSCLC; Glucose transporter; epigenetics

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

O'Byrne, K.J.; Baird, A.-M.; Kilmartin, L.; Leonard, J.; Sacevich, C.; Gray, S.G. Epigenetic Regulation of Glucose Transporters in Non-Small Cell Lung Cancer. Cancers 2011, 3, 1550-1565.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top